Thursday, December 21, 2023 3:35:22 PM
Biosect,
Let me be clear, I've not suggested selling the EDEN, I've suggested it be leased. I'm of the belief that the EDEN units will be computer controlled and NWBO would have complete access to what each of the units were doing. I also believe they'd totally control how the disposable cassettes are distributed and disposed of. In short, they could track every batch of vaccine regardless of who was making and distributing it as it would all be done by companies leasing the EDEN units from NWBO. The company would also be responsible for maintaining and upgrading all the leased equipment.
As to whether they'd be leased to one or two major CDMO's, or distributed to many by lease, would be up to the company. The key is that they wouldn't be responsible for the construction and maintenance of major cleanrooms, cryogenics, etc. They would be paid by all who're doing the work, and of course those companies would also profit from each batch they made and distributed as well.
Most companies who use CDMO's to produce their product don't provide the equipment it's produced on, but they're producing massive quantities of the product. We on the other hand have developed the means for producing each unique batch and are well positioned to lease the equipment to those we license to produce it. Barring that we'll need hundreds of millions or more to build the needed facilities ourself. I rather like the idea of doing this with other peoples money.
Gary
Let me be clear, I've not suggested selling the EDEN, I've suggested it be leased. I'm of the belief that the EDEN units will be computer controlled and NWBO would have complete access to what each of the units were doing. I also believe they'd totally control how the disposable cassettes are distributed and disposed of. In short, they could track every batch of vaccine regardless of who was making and distributing it as it would all be done by companies leasing the EDEN units from NWBO. The company would also be responsible for maintaining and upgrading all the leased equipment.
As to whether they'd be leased to one or two major CDMO's, or distributed to many by lease, would be up to the company. The key is that they wouldn't be responsible for the construction and maintenance of major cleanrooms, cryogenics, etc. They would be paid by all who're doing the work, and of course those companies would also profit from each batch they made and distributed as well.
Most companies who use CDMO's to produce their product don't provide the equipment it's produced on, but they're producing massive quantities of the product. We on the other hand have developed the means for producing each unique batch and are well positioned to lease the equipment to those we license to produce it. Barring that we'll need hundreds of millions or more to build the needed facilities ourself. I rather like the idea of doing this with other peoples money.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
